|
시장보고서
상품코드
1625487
면역치료제 시장 규모, 점유율, 동향, 산업 분석 보고서 : 유형별, 용도별, 투여 경로별, 최종사용자별, 지역별 - 시장 예측(2025-2034년)Immunotherapy Drugs Market Size, Share, Trends, Industry Analysis Report: By Type, Application, Route of Administration, End User, and Region - Market Forecast, 2025 - 2034 |
||||||
Polaris Market Research의 최신 조사에 따르면, 세계 면역치료제 시장 규모는 2034년까지 1조 1,520억 3,000만 달러에 달할 것으로 예상됩니다. 이 보고서는 현재 시장 역학에 대한 상세한 인사이트와 향후 시장 성장에 대한 분석을 제공합니다.
면역치료제 시장은 특정 세포나 경로를 표적으로 삼아 체내 면역체계를 이용하여 질병, 특히 암을 치료하는 의약품의 개발, 생산, 판매를 포함합니다. 기존 치료법보다 표적 치료제의 채택이 증가하고 있는 것이 면역치료제 시장의 성장을 크게 견인하고 있습니다. 단클론항체와 같은 표적 치료제는 암세포나 병원체를 특이적으로 공격하도록 설계되어 건강한 세포에 대한 손상을 최소화하고 화학요법과 같은 기존 치료에서 흔히 나타나는 부작용을 줄일 수 있습니다. 보다 정밀하고 효과적인 치료법으로의 전환은 유전자 및 질병 특성에 따라 환자 개개인의 프로파일에 맞는 치료를 제공하는 맞춤형 의료에 대한 수요 증가와 일치합니다. 그 결과, 면역치료제 시장의 수요는 예측 기간 동안 확대될 것으로 예상됩니다.
새로운 면역치료제의 승인과 용도 확대는 시장 성장을 더욱 촉진하고 있습니다. 예를 들어, 2024년 4월 아스트라제네카와 다이이찌산쿄의 엔허투(Enhertu)는 전이성 HER2 양성 고형암에 대한 최초의 종양 진단용 HER2 표적 치료제로 FDA의 승인을 받아 표적 면역치료 솔루션으로의 전환을 예시하고 있습니다.
이러한 발전은 치료 효과를 높이고, 종양학 및 기타 치료 분야에서 면역치료가 표준 치료 옵션으로 널리 받아들여지는 데 기여하고 있습니다. 다양한 암을 포함한 만성질환의 확산은 이러한 혁신적인 치료법에 대한 수요를 더욱 증가시켜 면역치료제 시장의 확장을 공고히 할 것으로 예상됩니다.
최근 헬스케어 기관 및 지원 단체의 지원으로 인한 인식 개선과 질병의 조기 발견이 적시에 치료를 유도하여 면역치료제 시장을 크게 활성화시키고 있습니다. 이러한 적극적인 접근을 통해 면역치료의 치료성적 향상에 대한 기대가 높아지고 있습니다. 또한, 공동 연구 및 연구개발에 대한 막대한 투자로 인한 바이오테크놀러지의 발전은 면역치료 솔루션의 혁신을 촉진하고 있습니다. 이는 치료 옵션의 확대와 환자 치료의 개선으로 시장 성장을 촉진하고 있습니다.
면역치료제 시장 보고서 하이라이트
항체의약품은 암 및 자가면역질환 치료에 있어 표적화된 정밀한 치료효과가 입증되어 면역치료제 시장을 독점하고 있습니다.
암 분야는 면역항암제 시장에서 가장 큰 점유율을 차지하고 있으며, 높은 미충족 의료 수요와 유망한 신치료제의 성과로 인해 앞으로도 우위를 유지할 것으로 예상됩니다.
북미는 높은 암 발병률, 탄탄한 의료 시스템, 생명공학에 대한 막대한 투자, 새로운 치료법의 빠른 도입 등으로 인해 2024년 이 시장에서 가장 큰 매출 점유율을 차지했습니다.
아시아태평양의 면역치료제 시장은 의료 인프라의 발전, 높은 질병 유병률, 강력한 임상시험 및 연구 파이프라인으로 인해 가장 빠르게 성장할 것으로 예상됩니다.
목차
제1장 소개
제2장 주요 요약
제3장 조사 방법
제4장 세계의 면역치료제 시장 인사이트
- 시장 현황
- 면역치료제 시장 역학
- 성장 촉진요인과 기회
- 면역요법 연구개발 활동의 진보
- 면역요법의 병용요법이 시장 성장을 견인
- 성장 억제요인과 과제
- 규제상 허들과 승인 지연
- 성장 촉진요인과 기회
- PESTEL 분석
- 면역치료제 시장 응용 동향
- 밸류체인 분석
- COVID-19의 영향 분석
제5장 세계의 면역치료제 시장 : 유형별
- 주요 조사 결과
- 소개
- 항체 의약품
- 억제제
- 인터페론과 인터류킨
- 백신
- 기타
제6장 세계의 면역치료제 시장 : 용도별
- 주요 조사 결과
- 소개
- 암
- 자가면역질환 및 염증성 질환
- 혈액학
- 골학
- 신경학
- 기타
제7장 세계의 면역치료제 시장 : 투여 경로별
- 주요 조사 결과
- 소개
- 정맥내
- 피하
- 경구
- 기타
제8장 세계의 면역치료제 시장 : 최종사용자별
- 주요 조사 결과
- 소개
- 병원
- 장기간병 시설
- 기타
제9장 세계의 면역치료제 시장 : 지역별
- 주요 조사 결과
- 소개
- 면역치료제 시장 평가 : 지역별, 2020-2034년
- 북미
- 북미 : 유형별, 2020-2034년
- 북미 : 투여 경로별, 2020-2034년
- 북미 : 용도별, 2020-2034년
- 북미 : 최종사용자별, 2020-2034년
- 미국
- 캐나다
- 유럽
- 유럽 : 유형별, 2020-2034년
- 유럽 : 투여 경로별, 2020-2034년
- 유럽 : 용도별, 2020-2034년
- 유럽 : 최종사용자별, 2020-2034년
- 영국
- 프랑스
- 독일
- 이탈리아
- 스페인
- 네덜란드
- 러시아
- 기타 유럽
- 아시아태평양
- 아시아태평양 : 유형별, 2020-2034년
- 아시아태평양 : 투여 경로별, 2020-2034년
- 아시아태평양 : 용도별, 2020-2034년
- 아시아태평양 : 최종사용자별, 2020-2034년
- 중국
- 인도
- 말레이시아
- 일본
- 인도네시아
- 한국
- 호주
- 기타 아시아태평양
- 중동 및 아프리카
- 중동 및 아프리카 : 유형별, 2020-2034년
- 중동 및 아프리카 : 투여 경로별, 2020-2034년
- 중동 및 아프리카 : 용도별, 2020-2034년
- 중동 및 아프리카 : 최종사용자별, 2020-2034년
- 사우디아라비아
- 아랍에미리트
- 이스라엘
- 남아프리카공화국
- 기타 중동 및 아프리카
- 라틴아메리카
- 라틴아메리카 : 유형별, 2020-2034년
- 라틴아메리카 : 투여 경로별, 2020-2034년
- 라틴아메리카 : 용도별, 2020-2034년
- 라틴아메리카 : 최종사용자별, 2020-2034년
- 멕시코
- 브라질
- 아르헨티나
- 기타 라틴아메리카
제10장 경쟁 구도
- 확대와 인수 분석
- 확대
- 인수
- 제휴/협업/합의/공개
제11장 기업 개요
- Abbvie Inc.
- Amgen Inc.
- AstraZeneca
- Bristol-Myers Squibb Company
- F. Hoffman-La Roche Ltd.
- Gilead Sciences, Inc.
- GSK PLC
- Johnson & Johnson Services, Inc.
- Merck & Co., Inc.
- Novartis AG
- Pfizer Inc.
- Sanofi
- Takeda Pharmaceutical Company Limited.
- Teva Pharmaceutical Industries Ltd.
The global immunotherapy drugs market size is expected to reach USD 1,152.03 billion by 2034, according to a new study by Polaris Market Research. The report "Immunotherapy Drugs Market Size, Share, Trends, Industry Analysis Report: By Type (Antibody Drugs, Inhibitor Drugs, Interferons and Interleukins, Vaccines, and Others), Application, Route of Administration, End User, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025 - 2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.
The immunotherapy drugs market involves the development, production, and sale of medications that use the body's immune system to treat diseases, particularly cancer, by targeting specific cells or pathways. The rising adoption of targeted therapy over traditional treatment methods is significantly driving the immunotherapy drugs market growth. Targeted therapies, such as monoclonal antibodies, are designed to specifically attack cancer cells or pathogens, which minimizes damage to healthy cells and reduces side effects commonly associated with conventional treatments such as chemotherapy. This shift towards more precise and effective treatments aligns with the increasing demand for personalized medicine, which tailors therapies to individual patient profiles based on genetic and disease characteristics. As a result, the immunotherapy drugs market demand is projected to grow over the forecast period.
The approval of new immunotherapy drugs and the expansion of their applications are further propelling market growth. For instance, in April 2024, AstraZeneca and Daiichi Sankyo's Enhertu were approved by the FDA as the first tumor-agnostic HER2-directed therapy for previously treated metastatic HER2-positive solid tumors, exemplifying the trend toward targeted immunotherapy solutions.
These advancements enhance treatment efficacy and also contribute to a broader acceptance of immunotherapy as a standard care option in oncology and other therapeutic areas. The growing prevalence of chronic diseases, including various cancers, is expected to increase the demand for these innovative therapies further, solidifying the immunotherapy drugs market expansion.
In recent years, increasing awareness and earlier detection of diseases, supported by healthcare organizations and advocacy groups, have significantly enhanced the immunotherapy drugs market by encouraging timely treatment. This proactive approach allows for better outcomes with immunotherapies. Further, advancements in biotechnology driven by research collaborations and substantial investments in R&D are fostering innovation in immunotherapy solutions. Together, these are expanding treatment options and improving patient care, thereby propelling market growth.
Immunotherapy Drugs Market Report Highlights
The antibody drugs segment dominated the immunotherapy drugs market due to their proven efficacy in treating cancers and autoimmune diseases with targeted precision.
The cancer segment held the largest immunotherapy drugs market share and is expected to remain dominant due to high unmet medical needs and the promising results of new therapies.
North America region held the largest revenue share of the market in 2024 due to high cancer prevalence, a robust healthcare system, significant investments in biotechnology, and rapid adoption of new therapies.
The immunotherapy drugs market in Asia Pacific is expected to grow fastest due to advancements in healthcare infrastructure, high disease incidence, and a strong pipeline of clinical trials and research.
The global key market players include Abbvie Inc.; Amgen Inc.; AstraZeneca; Bristol-Myers Squibb Company; F. Hoffman-La Roche Ltd.; Gilead Sciences, Inc.; GSK PLC; Johnson & Johnson Services, Inc.; Merck & Co., Inc.; Novartis AG; Pfizer Inc.; Sanofi; and others.
Polaris Market Research has segmented the immunotherapy drugs market report based on type, application, route of administration, end user, and region:
By Type Outlook
§ Antibody Drugs
§ Inhibitor Drugs
§ Interferons and Interleukins
§ Vaccines
§ Others
By Application Outlook
§ Cancer
§ Autoimmune and Inflammatory Diseases
§ Hematology
§ Osteology
§ Neurology
§ Others
By Route of Administration Outlook
§ Intravenous
§ Subcutaneous
§ Oral
§ Others
By End User Outlook
§ Hospitals
§ Long-Term Care Facilities
§ Others
By Regional Outlook
North America
US
Canada
Europe
Germany
UK
France
Italy
Spain
Russia
Netherlands
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Indonesia
Malaysia
Vietnam
Australia
Rest of Asia Pacific
Latin America
Argentina
Brazil
Mexico
Rest of Latin America
Middle East & Africa
UAE
Saudi Arabia
Israel
South Africa
Rest of Middle East & Africa
Table of Contents
1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
2. Executive Summary
- 2.1. Market Highlights
3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
4. Global Immunotherapy Drugs Market Insights
- 4.1. Immunotherapy Drugs Market - Market Snapshot
- 4.2. Immunotherapy Drugs Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Increasing Advancements in Immunotherapy Research & Development Activities
- 4.2.1.2. Combination Therapies in Immunotherapy Drives Market Growth
- 4.2.2. Restraints and Challenges
- 4.2.2.1. Regulatory Hurdles and Approval Delays
- 4.2.1. Drivers and Opportunities
- 4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTEL Analysis
- 4.5. Immunotherapy Drugs Market Application Trends
- 4.6. Value Chain Analysis
- 4.7. COVID-19 Impact Analysis
5. Global Immunotherapy Drugs Market, by Type
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. Global Immunotherapy Drugs Market, by Type, 2020-2034 (USD Billion)
- 5.3. Antibody Drugs
- 5.3.1. Global Immunotherapy Drugs Market, by Antibody Drugs, by Region, 2020-2034 (USD Billion)
- 5.4. Inhibitor Drugs
- 5.4.1. Global Immunotherapy Drugs Market, by Inhibitor Drugs, by Region, 2020-2034 (USD Billion)
- 5.5. Interferons and Interleukins
- 5.5.1. Global Immunotherapy Drugs Market, by Interferons and Interleukins, by Region, 2020-2034 (USD Billion)
- 5.6. Vaccines
- 5.6.1. Global Immunotherapy Drugs Market, by Vaccines, by Region, 2020-2034 (USD Billion)
- 5.7. Other
- 5.7.1. Global Immunotherapy Drugs Market, by Other, by Region, 2020-2034 (USD Billion)
6. Global Immunotherapy Drugs Market, by Application
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. Global Immunotherapy Drugs Market, by Application, 2020-2034 (USD Billion)
- 6.3. Cancer
- 6.3.1. Global Immunotherapy Drugs Market, by Cancer, by Region, 2020-2034 (USD Billion)
- 6.4. Autoimmune and Inflammatory Diseases
- 6.4.1. Global Immunotherapy Drugs Market, by Autoimmune and Inflammatory Diseases, by Region, 2020-2034 (USD Billion)
- 6.5. Hematology
- 6.5.1. Global Immunotherapy Drugs Market, by Hematology, by Region, 2020-2034 (USD Billion)
- 6.6. Osteology
- 6.6.1. Global Immunotherapy Drugs Market, by Osteology, by Region, 2020-2034 (USD Billion)
- 6.7. Neurology
- 6.7.1. Global Immunotherapy Drugs Market, by Neurology, by Region, 2020-2034 (USD Billion)
- 6.8. Other
- 6.8.1. Global Immunotherapy Drugs Market, by Other, by Region, 2020-2034 (USD Billion)
7. Global Immunotherapy Drugs Market, by Route of Administration
- 7.1. Key Findings
- 7.2. Introduction
- 7.2.1. Global Immunotherapy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
- 7.3. Intravenous
- 7.3.1. Global Immunotherapy Drugs Market, by Intravenous, by Region, 2020-2034 (USD Billion)
- 7.4. Subcutaneous
- 7.4.1. Global Immunotherapy Drugs Market, by Subcutaneous, by Region, 2020-2034 (USD Billion)
- 7.5. Oral
- 7.5.1. Global Immunotherapy Drugs Market, by Oral, by Region, 2020-2034 (USD Billion)
- 7.6. Other
- 7.6.1. Global Immunotherapy Drugs Market, by Other, by Region, 2020-2034 (USD Billion)
8. Global Immunotherapy Drugs Market, by End-User
- 8.1. Key Findings
- 8.2. Introduction
- 8.2.1. Global Immunotherapy Drugs Market, by End-User, 2020-2034 (USD Billion)
- 8.3. Hospitals
- 8.3.1. Global Immunotherapy Drugs Market, by Hospitals, by Region, 2020-2034 (USD Billion)
- 8.4. Long-Term Care Facilities
- 8.4.1. Global Immunotherapy Drugs Market, by Long-Term Care Facilities, by Region, 2020-2034 (USD Billion)
- 8.5. Other
- 8.5.1. Global Immunotherapy Drugs Market, by Other, by Region, 2020-2034 (USD Billion)
9. Global Immunotherapy Drugs Market, by Geography
- 9.1. Key Findings
- 9.2. Introduction
- 9.2.1. Immunotherapy Drugs Market Assessment, By Geography, 2020-2034 (USD Billion)
- 9.3. Immunotherapy Drugs Market - North America
- 9.3.1. North America: Immunotherapy Drugs Market, by Type, 2020-2034 (USD Billion)
- 9.3.2. North America: Immunotherapy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.3.3. North America: Immunotherapy Drugs Market, by Application, 2020-2034 (USD Billion)
- 9.3.4. North America: Immunotherapy Drugs Market, by End-User, 2020-2034 (USD Billion)
- 9.3.5. Immunotherapy Drugs Market - U.S.
- 9.3.5.1. U.S.: Immunotherapy Drugs Market, by Type, 2020-2034 (USD Billion)
- 9.3.5.2. U.S.: Immunotherapy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.3.5.3. U.S.: Immunotherapy Drugs Market, by Application, 2020-2034 (USD Billion)
- 9.3.5.4. U.S.: Immunotherapy Drugs Market, by End-User, 2020-2034 (USD Billion)
- 9.3.6. Immunotherapy Drugs Market - Canada
- 9.3.6.1. Canada: Immunotherapy Drugs Market, by Type, 2020-2034 (USD Billion)
- 9.3.6.2. Canada: Immunotherapy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.3.6.3. Canada: Immunotherapy Drugs Market, by Application, 2020-2034 (USD Billion)
- 9.3.6.4. Canada: Immunotherapy Drugs Market, by End-User, 2020-2034 (USD Billion)
- 9.4. Immunotherapy Drugs Market - Europe
- 9.4.1. Europe: Immunotherapy Drugs Market, by Type, 2020-2034 (USD Billion)
- 9.4.2. Europe: Immunotherapy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.4.3. Europe: Immunotherapy Drugs Market, by Application, 2020-2034 (USD Billion)
- 9.4.4. Europe: Immunotherapy Drugs Market, by End-User, 2020-2034 (USD Billion)
- 9.4.5. Immunotherapy Drugs Market - UK
- 9.4.5.1. UK: Immunotherapy Drugs Market, by Type, 2020-2034 (USD Billion)
- 9.4.5.2. UK: Immunotherapy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.4.5.3. UK: Immunotherapy Drugs Market, by Application, 2020-2034 (USD Billion)
- 9.4.5.4. UK: Immunotherapy Drugs Market, by End-User, 2020-2034 (USD Billion)
- 9.4.6. Immunotherapy Drugs Market - France
- 9.4.6.1. France: Immunotherapy Drugs Market, by Type, 2020-2034 (USD Billion)
- 9.4.6.2. France: Immunotherapy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.4.6.3. France: Immunotherapy Drugs Market, by Application, 2020-2034 (USD Billion)
- 9.4.6.4. France: Immunotherapy Drugs Market, by End-User, 2020-2034 (USD Billion)
- 9.4.7. Immunotherapy Drugs Market - Germany
- 9.4.7.1. Germany: Immunotherapy Drugs Market, by Type, 2020-2034 (USD Billion)
- 9.4.7.2. Germany: Immunotherapy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.4.7.3. Germany: Immunotherapy Drugs Market, by Application, 2020-2034 (USD Billion)
- 9.4.7.4. Germany: Immunotherapy Drugs Market, by End-User, 2020-2034 (USD Billion)
- 9.4.8. Immunotherapy Drugs Market - Italy
- 9.4.8.1. Italy: Immunotherapy Drugs Market, by Type, 2020-2034 (USD Billion)
- 9.4.8.2. Italy: Immunotherapy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.4.8.3. Italy: Immunotherapy Drugs Market, by Application, 2020-2034 (USD Billion)
- 9.4.8.4. Italy: Immunotherapy Drugs Market, by End-User, 2020-2034 (USD Billion)
- 9.4.9. Immunotherapy Drugs Market - Spain
- 9.4.9.1. Spain: Immunotherapy Drugs Market, by Type, 2020-2034 (USD Billion)
- 9.4.9.2. Spain: Immunotherapy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.4.9.3. Spain: Immunotherapy Drugs Market, by Application, 2020-2034 (USD Billion)
- 9.4.9.4. Spain: Immunotherapy Drugs Market, by End-User, 2020-2034 (USD Billion)
- 9.4.10. Immunotherapy Drugs Market - Netherlands
- 9.4.10.1. Netherlands: Immunotherapy Drugs Market, by Type, 2020-2034 (USD Billion)
- 9.4.10.2. Netherlands: Immunotherapy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.4.10.3. Netherlands: Immunotherapy Drugs Market, by Application, 2020-2034 (USD Billion)
- 9.4.10.4. Netherlands: Immunotherapy Drugs Market, by End-User, 2020-2034 (USD Billion)
- 9.4.11. Immunotherapy Drugs Market - Russia
- 9.4.11.1. Russia: Immunotherapy Drugs Market, by Type, 2020-2034 (USD Billion)
- 9.4.11.2. Russia: Immunotherapy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.4.11.3. Russia: Immunotherapy Drugs Market, by Application, 2020-2034 (USD Billion)
- 9.4.11.4. Russia: Immunotherapy Drugs Market, by End-User, 2020-2034 (USD Billion)
- 9.4.12. Immunotherapy Drugs Market - Rest of Europe
- 9.4.12.1. Rest of Europe: Immunotherapy Drugs Market, by Type, 2020-2034 (USD Billion)
- 9.4.12.2. Rest of Europe: Immunotherapy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.4.12.3. Rest of Europe: Immunotherapy Drugs Market, by Application, 2020-2034 (USD Billion)
- 9.4.12.4. Rest of Europe: Immunotherapy Drugs Market, by End-User, 2020-2034 (USD Billion)
- 9.5. Immunotherapy Drugs Market - Asia Pacific
- 9.5.1. Asia Pacific: Immunotherapy Drugs Market, by Type, 2020-2034 (USD Billion)
- 9.5.2. Asia Pacific: Immunotherapy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.5.3. Asia Pacific: Immunotherapy Drugs Market, by Application, 2020-2034 (USD Billion)
- 9.5.4. Asia Pacific: Immunotherapy Drugs Market, by End-User, 2020-2034 (USD Billion)
- 9.5.5. Immunotherapy Drugs Market - China
- 9.5.5.1. China: Immunotherapy Drugs Market, by Type, 2020-2034 (USD Billion)
- 9.5.5.2. China: Immunotherapy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.5.5.3. China: Immunotherapy Drugs Market, by Application, 2020-2034 (USD Billion)
- 9.5.5.4. China: Immunotherapy Drugs Market, by End-User, 2020-2034 (USD Billion)
- 9.5.6. Immunotherapy Drugs Market - India
- 9.5.6.1. India: Immunotherapy Drugs Market, by Type, 2020-2034 (USD Billion)
- 9.5.6.2. India: Immunotherapy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.5.6.3. India: Immunotherapy Drugs Market, by Application, 2020-2034 (USD Billion)
- 9.5.6.4. India: Immunotherapy Drugs Market, by End-User, 2020-2034 (USD Billion)
- 9.5.7. Immunotherapy Drugs Market - Malaysia
- 9.5.7.1. Malaysia: Immunotherapy Drugs Market, by Type, 2020-2034 (USD Billion)
- 9.5.7.2. Malaysia: Immunotherapy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.5.7.3. Malaysia: Immunotherapy Drugs Market, by Application, 2020-2034 (USD Billion)
- 9.5.7.4. Malaysia: Immunotherapy Drugs Market, by End-User, 2020-2034 (USD Billion)
- 9.5.8. Immunotherapy Drugs Market - Japan
- 9.5.8.1. Japan: Immunotherapy Drugs Market, by Type, 2020-2034 (USD Billion)
- 9.5.8.2. Japan: Immunotherapy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.5.8.3. Japan: Immunotherapy Drugs Market, by Application, 2020-2034 (USD Billion)
- 9.5.8.4. Japan: Immunotherapy Drugs Market, by End-User, 2020-2034 (USD Billion)
- 9.5.9. Immunotherapy Drugs Market - Indonesia
- 9.5.9.1. Indonesia: Immunotherapy Drugs Market, by Type, 2020-2034 (USD Billion)
- 9.5.9.2. Indonesia: Immunotherapy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.5.9.3. Indonesia: Immunotherapy Drugs Market, by Application, 2020-2034 (USD Billion)
- 9.5.9.4. Indonesia: Immunotherapy Drugs Market, by End-User, 2020-2034 (USD Billion)
- 9.5.10. Immunotherapy Drugs Market - South Korea
- 9.5.10.1. South Korea: Immunotherapy Drugs Market, by Type, 2020-2034 (USD Billion)
- 9.5.10.2. South Korea: Immunotherapy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.5.10.3. South Korea: Immunotherapy Drugs Market, by Application, 2020-2034 (USD Billion)
- 9.5.10.4. South Korea: Immunotherapy Drugs Market, by End-User, 2020-2034 (USD Billion)
- 9.5.11. Immunotherapy Drugs Market - Australia
- 9.5.11.1. Australia: Immunotherapy Drugs Market, by Type, 2020-2034 (USD Billion)
- 9.5.11.2. Australia: Immunotherapy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.5.11.3. Australia: Immunotherapy Drugs Market, by Application, 2020-2034 (USD Billion)
- 9.5.11.4. Australia: Immunotherapy Drugs Market, by End-User, 2020-2034 (USD Billion)
- 9.5.12. Immunotherapy Drugs Market - Rest of Asia Pacific
- 9.5.12.1. Rest of Asia Pacific: Immunotherapy Drugs Market, by Type, 2020-2034 (USD Billion)
- 9.5.12.2. Rest of Asia Pacific: Immunotherapy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.5.12.3. Rest of Asia Pacific: Immunotherapy Drugs Market, by Application, 2020-2034 (USD Billion)
- 9.5.12.4. Rest of Asia Pacific: Immunotherapy Drugs Market, by End-User, 2020-2034 (USD Billion)
- 9.6. Immunotherapy Drugs Market - Middle East & Africa
- 9.6.1. Middle East & Africa: Immunotherapy Drugs Market, by Type, 2020-2034 (USD Billion)
- 9.6.2. Middle East & Africa: Immunotherapy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.6.3. Middle East & Africa: Immunotherapy Drugs Market, by Application, 2020-2034 (USD Billion)
- 9.6.4. Middle East & Africa: Immunotherapy Drugs Market, by End-User, 2020-2034 (USD Billion)
- 9.6.5. Immunotherapy Drugs Market - Saudi Arabia
- 9.6.5.1. Saudi Arabia: Immunotherapy Drugs Market, by Type, 2020-2034 (USD Billion)
- 9.6.5.2. Saudi Arabia: Immunotherapy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.6.5.3. Saudi Arabia: Immunotherapy Drugs Market, by Application, 2020-2034 (USD Billion)
- 9.6.5.4. Saudi Arabia: Immunotherapy Drugs Market, by End-User, 2020-2034 (USD Billion)
- 9.6.6. Immunotherapy Drugs Market - UAE
- 9.6.6.1. UAE: Immunotherapy Drugs Market, by Type, 2020-2034 (USD Billion)
- 9.6.6.2. UAE: Immunotherapy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.6.6.3. UAE: Immunotherapy Drugs Market, by Application, 2020-2034 (USD Billion)
- 9.6.6.4. UAE: Immunotherapy Drugs Market, by End-User, 2020-2034 (USD Billion)
- 9.6.7. Immunotherapy Drugs Market - Israel
- 9.6.7.1. Israel: Immunotherapy Drugs Market, by Type, 2020-2034 (USD Billion)
- 9.6.7.2. Israel: Immunotherapy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.6.7.3. Israel: Immunotherapy Drugs Market, by Application, 2020-2034 (USD Billion)
- 9.6.7.4. Israel: Immunotherapy Drugs Market, by End-User, 2020-2034 (USD Billion)
- 9.6.8. Immunotherapy Drugs Market - South Africa
- 9.6.8.1. South Africa: Immunotherapy Drugs Market, by Type, 2020-2034 (USD Billion)
- 9.6.8.2. South Africa: Immunotherapy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.6.8.3. South Africa: Immunotherapy Drugs Market, by Application, 2020-2034 (USD Billion)
- 9.6.8.4. South Africa: Immunotherapy Drugs Market, by End-User, 2020-2034 (USD Billion)
- 9.6.9. Immunotherapy Drugs Market - Rest of Middle East & Africa
- 9.6.9.1. Rest of Middle East & Africa: Immunotherapy Drugs Market, by Type, 2020-2034 (USD Billion)
- 9.6.9.2. Rest of Middle East & Africa: Immunotherapy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.6.9.3. Rest of Middle East & Africa: Immunotherapy Drugs Market, by Application, 2020-2034 (USD Billion)
- 9.6.9.4. Rest of Middle East & Africa: Immunotherapy Drugs Market, by End-User, 2020-2034 (USD Billion)
- 9.7. Immunotherapy Drugs Market - Latin America
- 9.7.1. Latin America: Immunotherapy Drugs Market, by Type, 2020-2034 (USD Billion)
- 9.7.2. Latin America: Immunotherapy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.7.3. Latin America: Immunotherapy Drugs Market, by Application, 2020-2034 (USD Billion)
- 9.7.4. Latin America: Immunotherapy Drugs Market, by End-User, 2020-2034 (USD Billion)
- 9.7.5. Immunotherapy Drugs Market - Mexico
- 9.7.5.1. Mexico: Immunotherapy Drugs Market, by Type, 2020-2034 (USD Billion)
- 9.7.5.2. Mexico: Immunotherapy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.7.5.3. Mexico: Immunotherapy Drugs Market, by Application, 2020-2034 (USD Billion)
- 9.7.5.4. Mexico: Immunotherapy Drugs Market, by End-User, 2020-2034 (USD Billion)
- 9.7.6. Immunotherapy Drugs Market - Brazil
- 9.7.6.1. Brazil: Immunotherapy Drugs Market, by Type, 2020-2034 (USD Billion)
- 9.7.6.2. Brazil: Immunotherapy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.7.6.3. Brazil: Immunotherapy Drugs Market, by Application, 2020-2034 (USD Billion)
- 9.7.6.4. Brazil: Immunotherapy Drugs Market, by End-User, 2020-2034 (USD Billion)
- 9.7.7. Immunotherapy Drugs Market - Argentina
- 9.7.7.1. Argentina: Immunotherapy Drugs Market, by Type, 2020-2034 (USD Billion)
- 9.7.7.2. Argentina: Immunotherapy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.7.7.3. Argentina: Immunotherapy Drugs Market, by Application, 2020-2034 (USD Billion)
- 9.7.7.4. Argentina: Immunotherapy Drugs Market, by End-User, 2020-2034 (USD Billion)
- 9.7.8. Immunotherapy Drugs Market - Rest of Latin America
- 9.7.8.1. Rest of Latin America: Immunotherapy Drugs Market, by Type, 2020-2034 (USD Billion)
- 9.7.8.2. Rest of Latin America: Immunotherapy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.7.8.3. Rest of Latin America: Immunotherapy Drugs Market, by Application, 2020-2034 (USD Billion)
- 9.7.8.4. Rest of Latin America: Immunotherapy Drugs Market, by End-User, 2020-2034 (USD Billion)
10. Competitive Landscape
- 10.1. Expansion and Acquisition Analysis
- 10.1.1. Expansion
- 10.1.2. Acquisitions
- 10.2. Partnerships/Collaborations/Agreements/Exhibitions
11. Company Profiles
- 11.1. Abbvie Inc.
- 11.1.1. Company Overview
- 11.1.2. Financial Performance
- 11.1.3. Product Benchmarking
- 11.1.4. Recent Development
- 11.2. Amgen Inc.
- 11.2.1. Company Overview
- 11.2.2. Financial Performance
- 11.2.3. Product Benchmarking
- 11.2.4. Recent Development
- 11.3. AstraZeneca
- 11.3.1. Company Overview
- 11.3.2. Financial Performance
- 11.3.3. Product Benchmarking
- 11.3.4. Recent Development
- 11.4. Bristol-Myers Squibb Company
- 11.4.1. Company Overview
- 11.4.2. Financial Performance
- 11.4.3. Product Benchmarking
- 11.4.4. Recent Development
- 11.5. F. Hoffman-La Roche Ltd.
- 11.5.1. Company Overview
- 11.5.2. Financial Performance
- 11.5.3. Product Benchmarking
- 11.5.4. Recent Development
- 11.6. Gilead Sciences, Inc.
- 11.6.1. Company Overview
- 11.6.2. Financial Performance
- 11.6.3. Product Benchmarking
- 11.6.4. Recent Development
- 11.7. GSK PLC
- 11.7.1. Company Overview
- 11.7.2. Financial Performance
- 11.7.3. Product Benchmarking
- 11.7.4. Recent Development
- 11.8. Johnson & Johnson Services, Inc.
- 11.8.1. Company Overview
- 11.8.2. Financial Performance
- 11.8.3. Product Benchmarking
- 11.8.4. Recent Development
- 11.9. Merck & Co., Inc.
- 11.9.1. Company Overview
- 11.9.2. Financial Performance
- 11.9.3. Product Benchmarking
- 11.9.4. Recent Development
- 11.10. Novartis AG
- 11.10.1. Company Overview
- 11.10.2. Financial Performance
- 11.10.3. Product Benchmarking
- 11.10.4. Recent Development
- 11.11. Pfizer Inc.
- 11.11.1. Company Overview
- 11.11.2. Financial Performance
- 11.11.3. Product Benchmarking
- 11.11.4. Recent Development
- 11.12. Sanofi
- 11.12.1. Company Overview
- 11.12.2. Financial Performance
- 11.12.3. Product Benchmarking
- 11.12.4. Recent Development
- 11.13. Takeda Pharmaceutical Company Limited.
- 11.13.1. Company Overview
- 11.13.2. Financial Performance
- 11.13.3. Product Benchmarking
- 11.13.4. Recent Development
- 11.14. Teva Pharmaceutical Industries Ltd.
- 11.14.1. Company Overview
- 11.14.2. Financial Performance
- 11.14.3. Product Benchmarking
- 11.14.4. Recent Development
